ReviewEuropean journal of clinical pharmacology2010
The potential of cytokines as safety biomarkers for drug-induced liver injury.
Review in European journal of clinical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- From Compensation to Collapse: UVB-Driven Disruption of Host-Microbiota Homeostasis Exacerbates Amphibian Ecological Risk.Animals : an open access journal from MDPI · 2025Article
- Article
- Comparison of liver injury and inflammatory response following conventional and drug-eluting bead transcatheter chemoembolization in hepatocellular carcinoma.Discover oncology · 2025Article
- Probiotic bacteria protect against indomethacin-induced gastric ulcers through modulation of oxidative stress, inflammation, and apoptosis.Molecular biology reports · 2024Article
- Hepatoprotective effect of Nobiletin against 5-fluorouracil induce hepatotoxicity.Current research in pharmacology and drug discovery · 2024Article
- The immunological mechanisms and therapeutic potential in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity.Cell & bioscience · 2022Review
- Role of Platelet-activating factor and HO-1 in mediating the protective effect of rupatadine against 5-fluorouracil-induced hepatotoxicity in rats.Environmental science and pollution research international · 2022Article
- Circulatory Inflammatory Mediators in the Prediction of Anti-Tuberculous Drug-Induced Liver Injury Using RUCAM for Causality Assessment.Biomedicines · 2021Article
- Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury.Archives of toxicology · 2020Article
- In Vitro Veritas.Frontiers in toxicology · 2020Article
- Screening for Susceptibility-Related Factors and Biomarkers of Xianling Gubao Capsule-Induced Liver Injury.Frontiers in pharmacology · 2020Article
- Incidence, clinical features, and risk factors of fluoroquinolone-induced acute liver injury: a case-control study.Therapeutics and clinical risk management · 2019Article
- Susceptibility-Related Factor and Biomarkers of Dietary SupplementFrontiers in pharmacology · 2019Article
- In vitro prediction of drug-induced cholestatic liver injury: a challenge for the toxicologist.Archives of toxicology · 2018Article
- Dissecting the molecular pathophysiology of drug-induced liver injury.World journal of gastroenterology · 2018Review
- The protective effects of naringin against 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats.Iranian journal of basic medical sciences · 2018Article
- Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives.Current drug metabolism · 2018Review
- An Update on Adverse Outcome Pathways Leading to Liver Injury.Applied in vitro toxicology · 2017Review
- Protective Effect of 18Evidence-based complementary and alternative medicine : eCAM · 2017Article
- Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.BioMed research international · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Drug-induced liver injury (DILI) is an event that has a detrimental impact on drug development and patient safety; therefore the identification of novel biomarkers that are both sensitive and specific to the liver would have great benefit. Inflammation is known to be associated with human cases of DILI, and given the role of cytokines in modulating the inflammatory response, changes in cytokine expression patterns certainly show promise as potential biomarkers of DILI. Cytokines are interesting candidates for novel biomarkers as they are relatively accessible (by blood sampling) and accurately quantifiable. In particular, recent interest has developed in mechanism-specific, rather than tissue-specific, biomarkers. However, without fully understanding the role of inflammation in DILI and the role of cytokines in modulating the inflammatory response, cytokines may be limited in their use, being either diagnostic of the type of injury that has occurred and/or prognostic of outcome (recovery from DILI, cirrhosis, acute liver failure). Intracellular components released by damaged hepatocytes, although inaccessible and currently difficult to quantify, may be better biomarkers for the prognosis of severity of injury. In both cases there is a pressing need for the development and validation of assays sensitive enough and with a sufficient dynamic range to detect changes upon drug treatment. Although promising candidates are appearing in the literature, much remains to be done to understand the role of inflammation in DILI and the role that a given cytokine has in the inflammatory cascade associated with DILI before cytokines are viewed as biomarkers for DILI.
Indexed as
Identifiers
20694460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.